- Conditions
- Colorectal Cancer, Metastatic Colorectal Cancer, RAS Wild Type Colorectal Cancer, Refractory Colorectal Cancer
- Interventions
- Glutaminase Inhibitor CB-839, Panitumumab, Irinotecan Hydrochloride (phase I only), Laboratory Biomarker Analysis, Pharmacological Study, Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans
- Drug · Biological · Other + 1 more
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced May 21, 2026, 11:07 PM EDT